Care of Late-Stage Parkinsonism: Resource Utilization of the Disease in Five European Countries

Christopher Kruse, Anna Lipinski, Malte Verheyen, Monika Balzer-Geldsetzer, Michael Wittenberg, Stefan Lorenzl, Carmen Richinger, Christian Schmotz, Lars Tonges, Dirk Woitalla, Stephan Klebe, Bastiaan R Bloem, Adrianus Hommel, Wassilios G Meissner, Brice Laurens, Thomas Boraud, Alexandra Samier Foubert, Sylvain Vergnet, Francois Tison, Nadege Costa, Per Odin, Kristina Rosqvist, Jenny M Norlin, Frida Hjalte, Anette Schrag and Richard Dodel
Additional contact information
Christopher Kruse: Universität Duisburg-Essen = University of Duisburg-Essen [Essen]
Anna Lipinski: Universität Duisburg-Essen = University of Duisburg-Essen [Essen]
Malte Verheyen: Universität Duisburg-Essen = University of Duisburg-Essen [Essen]
Monika Balzer-Geldsetzer: Universität Duisburg-Essen = University of Duisburg-Essen [Essen]
Michael Wittenberg: Philipps Universität Marburg = Philipps University of Marburg
Stefan Lorenzl: LMU - Ludwig Maximilian University [Munich] = Ludwig Maximilians Universität München
Wassilios G Meissner: IMN - Institut des Maladies Neurodégénératives [Bordeaux] - UB - Université de Bordeaux - CNRS - Centre National de la Recherche Scientifique
Brice Laurens: IMN - Institut des Maladies Neurodégénératives [Bordeaux] - UB - Université de Bordeaux - CNRS - Centre National de la Recherche Scientifique
Thomas Boraud: IMN - Institut des Maladies Neurodégénératives [Bordeaux] - UB - Université de Bordeaux - CNRS - Centre National de la Recherche Scientifique
Alexandra Samier Foubert: IMN - Institut des Maladies Neurodégénératives [Bordeaux] - UB - Université de Bordeaux - CNRS - Centre National de la Recherche Scientifique, BPH - Bordeaux population health - UB - Université de Bordeaux - Institut de Santé Publique, d'Épidémiologie et de Développement (ISPED) - INSERM - Institut National de la Santé et de la Recherche Médicale
Sylvain Vergnet: IMN - Institut des Maladies Neurodégénératives [Bordeaux] - UB - Université de Bordeaux - CNRS - Centre National de la Recherche Scientifique
Francois Tison: IMN - Institut des Maladies Neurodégénératives [Bordeaux] - UB - Université de Bordeaux - CNRS - Centre National de la Recherche Scientifique
Nadege Costa: CHU Toulouse - Centre Hospitalier Universitaire de Toulouse, Equipe EQUITY (CERPOP) - CERPOP - Centre d'Epidémiologie et de Recherche en santé des POPulations - UT3 - Université Toulouse III - Paul Sabatier - UT - Université de Toulouse - INSERM - Institut National de la Santé et de la Recherche Médicale
Per Odin: Lund University
Kristina Rosqvist: Lund University
Richard Dodel: Universität Duisburg-Essen = University of Duisburg-Essen [Essen], Philipps Universität Marburg = Philipps University of Marburg

Post-Print from HAL

Abstract: BACKGROUND: Parkinson's disease (PD) is a neurodegenerative disease that leads to progressive disability. Cost studies have mainly explored the early stages of the disease, whereas late-stage patients are underrepresented. OBJECTIVE: The aim is to evaluate the resource utilization and costs of PD management in people with late-stage disease. METHODS: The Care of Late-Stage Parkinsonism (CLaSP) study collected economic data from patients with late-stage PD and their caregivers in five European countries (France, Germany, the Netherlands, UK, Sweden) in a range of different settings. Patients were eligible to be included if they were in Hoehn and Yahr stage >3 in the on state or Schwab and England stage at 50% or less. In total, 592 patients met the inclusion criteria and provided information on their resource utilization. Costs were calculated from a societal perspective for a 3-month period. A least absolute shrinkage and selection operator approach was utilized to identify the most influential independent variables for explaining and predicting costs. RESULTS: During the 3-month period, the costs were €20,573 (France), €19,959 (Germany), €18,319 (the Netherlands), €25,649 (Sweden), and €12,156 (UK). The main contributors across sites were formal care, hospitalization, and informal care. Gender, age, duration of the disease, Unified Parkinson's Disease Rating Scale 2, the EQ-5D-3L, and the Schwab and England Scale were identified as predictors of costs. CONCLUSION: Costs in this cohort of individuals with late-stage PD were substantially higher compared to previously published data on individuals living in earlier stages of the disease. Resource utilization in the individual sites differed in part considerably among these three parameters mentioned. © 2024 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.

Keywords: Cost-of-illness; Parkinson’s disease; resource utilization; late-stage parkinsonism (search for similar items in EconPapers)
Date: 2024
Note: View the original document on HAL open archive server: https://hal.science/hal-04501150v1
References: View complete reference list from CitEc
Citations:

Published in Movement Disorders, inPress, ⟨10.1002/mds.29718⟩

Downloads: (external link)
https://hal.science/hal-04501150v1/document (application/pdf)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:hal:journl:hal-04501150

DOI: 10.1002/mds.29718

Access Statistics for this paper

More papers in Post-Print from HAL
Bibliographic data for series maintained by CCSD ().